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Increasingly, physicians and patients face dilemmas of whether to exclude genetic
information from medical charts, posing critical challenges for practice, research, policy,
and education. Physicians and patients are obtaining more genetic information, yet medical
records are rapidly becoming electronic, threatening confidentiality. Tensions thus arise
between potential medical benefits vs social risks of including information. Use of genetic
testing is rapidly increasing through clinicians and direct-to-consumer marketing. Direct-to-
consumer tests may be definitive or show only slightly increased disease probabilities, but
with advances may have increasing clinical utility. Several institutions have also discussed
including whole genome data in medical records. Genetic discrimination has occurred with
α1-antitrypsin deficiency, Huntington disease, and other mutations,1 although the extent
remains unclear,2 partly because such discrimination can be subtle or difficult to prove.
Patients may be passed over for promotion or marginalized, but not fired.3
The Health Insurance Portability and Accountability Act (HIPAA) protects medical
information in certain contexts and the 2008 Genetic Information Nondiscrimination Act
(GINA) protects genetic test results in the absence of symptoms, but these laws do not
prevent discrimination in many realms (eg, life, disability, or long-term care insurance).
Many patient advocates are concerned that under GINA, discriminating against patients and
paying fines may cost companies less than covering them—as racial, sex, and age
discrimination continue, despite legislation. Federal health care reforms of 2010 should
broaden coverage of preexisting conditions but have yet to be implemented, and advocates
are concerned that reforms might simply raise premiums.
Patients’ Views
Recent interviews conducted with patients confronting several genetic diseases highlight
several challenges,3,4 including concerns about storing genetic information. Patients often
did not trust how laws would work in real-world circumstances; whether subtle/indirect
discrimination, difficult to demonstrate, might occur.3 These interviews, along with other,
anecdotal evidence, suggest that many patients thus remain wary of providing results to
physicians, assuming that all information will be entered into medical records. Hence, some
patients may withhold information. Moreover, information, once in charts, may be virtually
impossible to remove. Some support groups run by patient organizations have encouraged
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patients to ask physicians to exclude genetic information from the medical record. Some
patients may not reveal information to their physicians until they are assured it will not
appear in their medical record.
Physician Decisions
The American Medical Association Code of Medical Ethics states that “it may be necessary
for physicians to maintain separate files for genetic testing results to ensure that the results
are not sent to health insurance companies. . . . Physicians who withhold . . . results should
inform insurance companies that, when medical records are sent, genetic testing results are
not included.”5
However, health care systems may not allow this option of stating that some information is
excluded, and physicians may face adverse legal and institutional consequences. Insurers
may insist on obtaining the data, arguing that such data are relevant, and may not cover fees
for patient care unless all information is received. Moreover, physicians, in stating that
genetic information may be excluded, might inadvertently alert insurers that a serious
mutation exists.
Physician sensitivity and approaches concerning these issues appear to vary. Some might
voluntarily exclude information, keep separate, parallel “shadow” charts (without telling
insurers that sent records exclude information), or encode information, using broad generic
terms, not specific diagnoses.6 However, office staff may not appreciate this need for
nondocumentation and inadvertently forward information.
Although patients may want to exclude information that involves potential harm to a third
party (eg, relatives), physicians may be obliged to not only document but also report that
information to external agencies. Judges have ruled that physicians sometimes have duties to
warn third parties about genetic risks.7 Hence physicians, in not documenting the genetic
information or ways they are handling the situation (eg, whether they or patients are
disclosing that information to family members), may be endangering themselves. Physicians
might disguise information and justify this behavior,8 but as a result they could face ethical
and legal problems.
Questions emerge about whether physicians can or should also exclude other kinds of
genetic information (eg, family members’ genetic test results or risks), and if so, when and
how; and whether to then also inform insurers that medical records exclude these data.
Alternatively, physicians, concerned about liability or discounting discrimination, may
document information, even refusing patients’ requests for exclusion.
Omitting genetic information has medical risks. With certain genetically associated
syndromes such as myotonic dystrophy and breast cancer, excluded information may pose
problems if patients are seen by other physicians who can access only the information
documented in the medical record. For rare disorders, clinicians may overlook diagnoses
and order additional, unnecessary tests to rule out more common but absent diseases. Breast
cancer mutations can affect treatment decisions. In omitting or disguising information,
physicians may also devalue the medical record, undermining patients’ and physicians’ trust
in it and each other, and reinforcing fears that genetic tests indeed cause discrimination.
Moreover, increasing health care system fragmentation makes the medical record one of the
only vehicles for continuity in care.
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Attention and research are needed to address questions such as how often and when patients
request excluding genetic information and also when physicians omit that information or
record it in code or separate charts; what the legal status of shadow charts are in different
states; how insurers do or will respond; how much patients and clinicians value
completeness of medical records; and how often patients experience or have concern about
genetic discrimination.
Ethical dilemmas emerge about when physicians should exclude certain genetic information
and how to decide whether to exclude it or not. Physicians ordinarily have no contractual
duty to give information to patients’ employers, but they face tensions between medical
benefits and social risks (eg, possible stigma/discrimination) of including information. One
can argue that information, if irrelevant to patients’ health, can be omitted. But views of
relevance, based on probabilities of future medical events, can be uncertain. How to resolve
clinician, insurer, and patient disagreements is also unclear.
Professional and public education is crucial. Some physicians have a poor understanding of
genetics,9 but given genetic counselor shortages, need to become more sensitive to these
areas, prepare to counsel patients about these issues, and be open to patient requests,
realizing that patients may withhold information. Physicians should obtain informed consent
regarding these options by educating patients about the risks and benefits of disclosing
genetic information, the scope and limitations of current policies, safeguards and guidelines,
the choices available, and the advantages and disadvantages to recording genetic
information in the medical record. Before promising confidentiality, clinicians should ensure
that patients understand its limitations.10 Deciding whether to chart direct-to-consumer
testing and, if so, when raises additional concerns. Physicians can also consider suggesting
that patients contemplate obtaining disability, life, or long-term care insurance before
testing.
These choices pose potential risks and benefits, embodying difficult-to-weigh uncertainties.
Yet presenting these considerations can help patients and physicians think through these
options together. Physicians should realize that patients’ preferences will vary with specific
diseases and genetics and extent of patients’ discrimination concerns.
Current guidelines should be revisited; threats to confidentiality remain real. Careful,
sensitive implementation of GINA can reduce discrimination fears, but legislation is needed
to cover other forms of insurance and increase fines if employers or health care insurers
violate GINA.
In electronic medical records, 2-tiered systems for sensitive vs other information may help,
but details remain to be determined (eg, who exactly would have access). Health, disability,
and life insurers may well still demand full information. How well such complex systems
will work or assuage patients’ concerns is unclear. Other kinds of sensitive (eg, psychiatric)
information pose related, although sometimes differing, issues also requiring attention and
further research.
Increasing threats to confidentiality will surely perpetuate desires of patients and physicians
to exclude information. Clinicians should recognize and address, not ignore, these
challenges to attend closely to these critical concerns.
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